| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/19/2009 | US20090285753 Novel haptotactic peptides |
| 11/19/2009 | CA2725235A1 Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment |
| 11/19/2009 | CA2724804A1 Therapy regimen for treating acne related diseases |
| 11/19/2009 | CA2724246A1 Anticancer combination therapy including triciribine |
| 11/19/2009 | CA2724206A1 Multiple myeloma treatments |
| 11/19/2009 | CA2724133A1 Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine |
| 11/19/2009 | CA2723623A1 Therapeutic agent for pain |
| 11/18/2009 | EP2119785A1 Novel peptides |
| 11/18/2009 | EP2119715A1 Benzimidazole derivative and its use as aii receptor antagonist |
| 11/18/2009 | EP2119441A1 Use of angiotensin II receptor antagonists in order to increase insulin sensitivity |
| 11/18/2009 | EP2119438A1 Bone metabolism ameliorating agent |
| 11/18/2009 | EP2118133A2 Amelioration of cellular stress response |
| 11/18/2009 | EP2117565A2 Use of chitosans for the treatment of nail inflammatory diseases |
| 11/18/2009 | EP2117555A1 Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
| 11/18/2009 | EP2117543A2 Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| 11/18/2009 | EP2117356A1 Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition |
| 11/18/2009 | EP1711518B1 Chimpanzee adenovirus vaccine carriers |
| 11/18/2009 | EP1587474B1 Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| 11/18/2009 | EP1545453B1 Rifalazil for treating infections of clostridium difficile |
| 11/18/2009 | EP1413303B1 Swine growth promoters and method of promoting swine growth |
| 11/18/2009 | EP1207873B1 Methods of inhibiting osteoclast activity |
| 11/18/2009 | EP1079875B2 Cancer treatment by ultrapheresis removing compounds of less than 120,000 daltons |
| 11/18/2009 | EP0960127B1 Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 11/18/2009 | EP0957901B1 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 11/18/2009 | EP0914422B1 Mammalian genes involved in viral infection |
| 11/18/2009 | EP0904112B1 Composition comprising il-1ra as interleukin-1 inhibitor and hyaluronan as controlled release polymer |
| 11/18/2009 | CN101583377A Treatment of fibrosis |
| 11/18/2009 | CN101583373A Therapeutic agent for interstitial pneumonia |
| 11/18/2009 | CN101583366A Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 11/18/2009 | CN101583359A Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
| 11/18/2009 | CN101583357A Composition of mTOR antagonist and angiogenesis inhibitor for treating cancer |
| 11/18/2009 | CN101583355A Renin inhibitors for the prevention and treatment of hypertension in obese patients |
| 11/18/2009 | CN101580871A Method for screening new drug for lowering cholesterol based on analysis of change of NPC1L1 protein subcellular localization |
| 11/18/2009 | CN101580536A Macrocyclic ns-3 serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 11/18/2009 | CN101579362A Compositions and method for tumor-target delivery of effect molecules |
| 11/18/2009 | CN101579314A Anti-cancer drug sustained-release preparation of organic-inorganic complex liposome and preparation method thereof |
| 11/18/2009 | CN100560132C Contraception process and administration for same |
| 11/18/2009 | CN100560129C Use of inhibitors of enzymes with APN and/or DPIV activity for the treatment of dermatological diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts |
| 11/18/2009 | CN100560075C Medicine for modulating lipid metabolism |
| 11/18/2009 | CN100560059C Co-grinding process for the preparation of a ternary composition |
| 11/17/2009 | US7619091 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) |
| 11/17/2009 | US7619057 Cancer antigen peptide and/or major histocompatibility complex binding sites for use as tools in detection and tretment of cell proliferative disorders; immunotherapy; genetic vaccine |
| 11/17/2009 | US7618994 Such as (+/-)-[9-(4-chlorobenzyl)-6-fluoro-8-methanesulfonyl-2, 3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid; prostaglandin receptor antagonists; antihistamines; nasal decongestion, rhinitis |
| 11/17/2009 | US7618988 Use of substituted aminomethyl chromans |
| 11/17/2009 | US7618940 Identidying modulators of hypoxia inducible factor protein for use in controlling fat metabolism and prevention and treating of obesity, diabetes and atherosclerosis |
| 11/17/2009 | US7618818 Method for detecting leptin receptor ligands |
| 11/17/2009 | US7618791 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 11/17/2009 | US7618787 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelarator and apoptosis inhibitor |
| 11/17/2009 | US7618786 Method for identifying modulators of human orexin-2 receptor |
| 11/17/2009 | US7618785 Diagnostic and therapeutic methods based on the L1 adhesion molecule for ovarian and endometrial tumors |
| 11/17/2009 | US7618649 For therapy of nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis |
| 11/17/2009 | US7618640 Method and composition for reducing E. coli disease and enhancing performance |
| 11/17/2009 | CA2588495C The utility of uridine nucleosides in the treatment of cachexia |
| 11/17/2009 | CA2444551C Microprojection array immunization patch and method |
| 11/17/2009 | CA2444501C Phenylindoles for the treatment of hiv |
| 11/17/2009 | CA2441239C Mch antagonists and their use in the treatment of obesity |
| 11/17/2009 | CA2411172C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 11/17/2009 | CA2397244C Ace inhibitor-vasopressin antagonist combinations |
| 11/17/2009 | CA2393809C Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 11/17/2009 | CA2379365C Transnasal anticonvulsive compositions and modulated process |
| 11/17/2009 | CA2366897C Immunomodulatory compositions and methods of use thereof |
| 11/17/2009 | CA2352494C Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases |
| 11/17/2009 | CA2341429C Treatment of mucus hypersecretion |
| 11/17/2009 | CA2336822C Method of treatment and pharmaceutical composition |
| 11/17/2009 | CA2304973C Stabilized preparations for use in nebulizers |
| 11/17/2009 | CA2254394C Method and composition for the treatment and prevention of hyperuricemia |
| 11/12/2009 | WO2009137378A2 Sequential administration of chemotherapeutic agents for treatment of cancer |
| 11/12/2009 | WO2009137074A1 Compositions and methods for treating diabetic ulcers |
| 11/12/2009 | WO2009136629A1 Prophylactic/therapeutic agent for lifestyle-related diseases |
| 11/12/2009 | WO2009136587A1 Anti-fatigue composition |
| 11/12/2009 | WO2009136396A2 Sulfobetaines for therapy |
| 11/12/2009 | WO2009135614A2 Use of a virus regimen for the treatment of diseases |
| 11/12/2009 | WO2009111691A3 Combination therapy with c-met and egfr antagonists |
| 11/12/2009 | WO2009056232A3 Combination of pde5 inhibitors with muscarinic receptor antagonists |
| 11/12/2009 | US20090281196 1-adamantyl chalcones for the treatment of proliferative disorders |
| 11/12/2009 | US20090280192 Method for treating or preventing alzheimer's disease |
| 11/12/2009 | US20090280168 Chlamydia polypeptides used to prevent, treat, and diagnose Chlamydia infection; 98 KDa OMP antigen designated CPN100686 RY 54 |
| 11/12/2009 | US20090280164 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 11/12/2009 | US20090280117 Methods for the treatment or prevention of immune disorders using anti-cd40 antibodies |
| 11/12/2009 | US20090280095 Cell culture of keratinocytes under non-differentiating conditions |
| 11/12/2009 | US20090280081 JAK/STAT pathway inhibitors and uses thereof |
| 11/12/2009 | CA2723440A1 Sulfobetaines for therapy |
| 11/12/2009 | CA2722992A1 Sequential administration of chemotherapeutic agents for treatment of cancer |
| 11/11/2009 | EP2116616A2 Genes differentially expressed in activated T cells and uses thereof |
| 11/11/2009 | EP2116543A1 Novel aminopyrimidine derivative as plk1 inhibitor |
| 11/11/2009 | EP2116524A1 Method for the synthesis of the sodium salt of retinoyl-cysteic acid and retinoyl-cysteine sulfinic acid |
| 11/11/2009 | EP2116523A1 Rexinoid compound having alkoxy group |
| 11/11/2009 | EP2116266A1 Percutaneously absorbable preparation, process for production thereof and method for percutaneous absorption |
| 11/11/2009 | EP2116264A1 Preparation for transnasal application |
| 11/11/2009 | EP2116262A2 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| 11/11/2009 | EP2116247A2 Anti-amnesia compounds and pharmaceutical compositions comprising same |
| 11/11/2009 | EP2116245A2 EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders |
| 11/11/2009 | EP2116240A1 Augmented cognitive training with HT0712 |
| 11/11/2009 | EP2116237A1 Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| 11/11/2009 | EP1729808B1 Combination therapy with azd2171 and 5-fu and/or cpt-11 |
| 11/11/2009 | EP1729807B1 Combination therapy with azd-2171 |
| 11/11/2009 | EP1492487B1 Mitotic kinesin inhibitors |
| 11/11/2009 | EP1477186B1 Antipruritics |
| 11/11/2009 | EP1450856B1 Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| 11/11/2009 | EP1364659B1 Remedies for urinary diseases comprising lpa receptor controlling agents |